Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Emma C. Tallantyre et al.
Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.
ANNALS OF NEUROLOGY
(2022)
Article
Clinical Neurology
Carla Tortorella et al.
Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study compares the outcomes of COVID-19 in patients with multiple sclerosis (MS) in Italy with the expected outcomes in the general population. The risk of severe events, including hospitalization, ICU admission, and death, was found to be twice as high in the MS cohort compared to the age- and sex-matched Italian population. The increased risk was primarily associated with disease severity and comorbidities, but there was also a higher risk of hospitalization in patients on anti-CD20 therapies and a lower risk in patients on interferon.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Maria P. Sormani et al.
Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.
ANNALS OF NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.
Article
Clinical Neurology
Deja R. Rose et al.
Summary: Studies have shown reduced serological response to vaccines in patients on anti-CD20 agents, but limited data exist on vaccine efficacy in patients on disease modifying therapy (DMT). This study aimed to investigate breakthrough COVID-19 cases in vaccinated people with multiple sclerosis on DMT. Results showed that a small percentage of fully vaccinated patients on DMT were diagnosed with COVID-19, with most cases on anti-CD20 therapy and only a few requiring hospitalization. Further research is needed to analyze the risk of COVID-19 in patients on different therapies, especially in the context of emerging variants.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2021)
Article
Clinical Neurology
Anat Achiron et al.
Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Infectious Diseases
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES
(2020)
Article
Statistics & Probability
LD Brown et al.
STATISTICAL SCIENCE
(2001)